{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:03:51Z","timestamp":1768917831588,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to investigate the contralateral breast cancer (CBC) recurrence rate in Korean breast cancer patients according to their <jats:italic>BRCA1\/2<\/jats:italic> germline mutation status, focusing particularly on the CBC recurrence risk in <jats:italic>BRCA1\/2<\/jats:italic> negative (<jats:italic>BRCAx<\/jats:italic>) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective study on 13,107 primary breast cancer patients. The patients were divided into high-risk and low-risk groups for hereditary breast cancer based on the Korean National Health Insurance Service\u2019s eligibility criteria for <jats:italic>BRCA1\/2<\/jats:italic> germline mutation testing. The high-risk group was further categorized into the <jats:italic>BRCA<\/jats:italic><jats:italic>mutation group<\/jats:italic>, the <jats:italic>BRCAx<\/jats:italic><jats:italic>group<\/jats:italic>, and the <jats:italic>not tested group<\/jats:italic>. We evaluated the overall survival and cumulative risk of developing CBC in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 4494 high-risk patients, 973 (21.7%) underwent genetic testing for <jats:italic>BRCA1\/2<\/jats:italic> germline mutation, revealing mutations in 158 patients (16.2%). We observed significant overall survival differences across all four groups, with the high-risk, not-tested group demonstrating notably worse overall survival (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). However, when adjusted for other prognostic factors, there was no significant differences in hazard ratio of death between the four groups. The cumulative risk of CBC also varied among the groups. Patients with <jats:italic>BRCA1\/2<\/jats:italic> mutations showed a 7.3-fold increased risk of CBC compared to the low-risk group (95% CI 4.11\u201313.0, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Interestingly, <jats:italic>BRCAx<\/jats:italic> patients also demonstrated a significantly higher risk of CBC (HR 2.77, 95% CI 1.76\u20134.35, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The prognostic importance of the <jats:italic>BRCAx<\/jats:italic> for CBC recurrence persisted after adjusting for the age and subtype, but became insignificant when the family history of breast cancer was adjusted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Breast cancer patients who are at high risk of hereditary breast cancer but with wild-type <jats:italic>BRCA 1\/2<\/jats:italic> genes (<jats:italic>BRCAx<\/jats:italic>) have increased risk of developing contralateral breast cancer when compared to the low-risk patients. More careful surveillance and follow-up can be offered to these patients especially when they have family history of breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-024-01769-x","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T10:03:01Z","timestamp":1705917781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased risk of contralateral breast cancer for BRCA1\/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Eunhye","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Jung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong-Gon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"1","key":"1769_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMra0802968","volume":"359","author":"WD Foulkes","year":"2008","unstructured":"Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143\u201353.","journal-title":"N Engl J Med"},{"issue":"5182","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66\u201371.","journal-title":"Science"},{"issue":"6559","key":"1769_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789\u201392.","journal-title":"Nature"},{"issue":"5","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665\u201376.","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"1769_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"11","key":"1769_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1769_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10549-015-3377-4","volume":"151","author":"E Kang","year":"2015","unstructured":"Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151(1):157\u201368.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1769_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4048\/jbc.2013.16.3.245","volume":"16","author":"E Kang","year":"2013","unstructured":"Kang E, Kim SW. The korean hereditary breast cancer study: review and future perspectives. J Breast Cancer. 2013;16(3):245\u201353.","journal-title":"J Breast Cancer"},{"issue":"4","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s10038-020-00850-5","volume":"66","author":"A Yoshimura","year":"2021","unstructured":"Yoshimura A, Yokoyama S, Iwata H, Takaiso N, Nomizu T, Arai M, et al. Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1\/2 pathogenic variant carriers based on the Japanese HBOC consortium registration. J Hum Genet. 2021;66(4):379\u201387.","journal-title":"J Hum Genet"},{"issue":"2","key":"1769_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-018-5015-4","volume":"173","author":"JM Ryu","year":"2019","unstructured":"Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, et al. Prevalence and oncologic outcomes of BRCA 1\/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173(2):385\u201395.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1769_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4048\/jbc.2021.24.e22","volume":"24","author":"SY Kang","year":"2021","unstructured":"Kang SY, Lee SB, Kim YS, Kim Z, Kim HY, Kim HJ, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer. 2021;24(2):123\u201337.","journal-title":"J Breast Cancer"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/978-981-32-9620-6_24","volume":"1187","author":"ES Lee","year":"2021","unstructured":"Lee ES, Kim J, Han W. Multigene panel testing for hereditary cancer and genetic counseling. Adv Exp Med Biol. 2021;1187:455\u201371.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1769_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10549-004-2172-4","volume":"89","author":"M Lacroix","year":"2005","unstructured":"Lacroix M, Leclercq G. The, \u201cportrait\u201d of hereditary breast cancer. Breast Cancer Res Treat. 2005;89(3):297\u2013304.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1769_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ejso.2015.01.021","volume":"41","author":"F Aloraifi","year":"2015","unstructured":"Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O\u2019Doherty A, et al. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer. Eur J Surg Oncol. 2015;41(5):641\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1769_CR17","doi-asserted-by":"publisher","first-page":"15263","DOI":"10.1038\/s41598-018-31859-8","volume":"8","author":"JY Lee","year":"2018","unstructured":"Lee JY, Kim J, Kim SW, Park SK, Ahn SH, Lee MH, et al. BRCA1\/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts. Sci Rep. 2018;8(1):15263.","journal-title":"Sci Rep"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10549-015-3419-y","volume":"151","author":"TS Menes","year":"2015","unstructured":"Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015;151:653\u201360.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1769_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4048\/jbc.2019.22.e47","volume":"22","author":"K-H Yoon","year":"2019","unstructured":"Yoon K-H, Chae S, Kang E, Shin H-C, Kim JH, Kim IA, et al. Contralateral breast cancer and ipsilateral breast tumor recurrence in BRCA1\/2 carriers and non-carriers at high-risk of hereditary breast cancer. J Breast Cancer. 2019;22(4):587\u201398.","journal-title":"J Breast Cancer"},{"issue":"16","key":"1769_CR20","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J Clin Oncol. 2006;24(16):2437\u201343.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1769_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-021-06446-7","volume":"192","author":"P-H Lin","year":"2022","unstructured":"Lin P-H, Chen S-C, Tseng L-M, Chang K-J, Huang A-C, Cheng K-C, et al. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res Treat. 2022;192(3):629\u201337.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1769_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkj\u00e6r L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women\u2019s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1769_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","volume":"43","author":"C Brekelmans","year":"2007","unstructured":"Brekelmans C, Tilanus-Linthorst M, Seynaeve C, vd Ouweland A, Menke-Pluymers M, Bartels C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1\/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43(5):867\u201376.","journal-title":"Eur J Cancer"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M, et al. The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 2012;14:1\u20138.","journal-title":"Breast Cancer Res"},{"key":"1769_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-005-9054-2","volume":"95","author":"MM Tilanus-Linthorst","year":"2006","unstructured":"Tilanus-Linthorst MM, Bartels KC, Alves C, Bakri B, Crepin E, van den Ouweland A, et al. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1\/2 patients. Breast Cancer Res Treat. 2006;95:117\u201323.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"1769_CR26","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2017.77.3424","volume":"36","author":"AS Reiner","year":"2018","unstructured":"Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkj\u00e6r L, et al. Breast cancer family history and contralateral breast cancer risk in young women: an update from the women\u2019s environmental cancer and radiation epidemiology study. J Clin Oncol. 2018;36(15):1513\u201320.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1769_CR27","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1038\/sj.bjc.6603753","volume":"96","author":"E Couto","year":"2007","unstructured":"Couto E, Hemminki K. Estimates of heritable and environmental components of familial breast cancer using family history information. Br J Cancer. 2007;96(11):1740\u20132.","journal-title":"Br J Cancer"},{"issue":"2","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169\u201380.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1769_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","volume":"30","author":"PJ Goodwin","year":"2012","unstructured":"Goodwin PJ, Phillips K-A, West DW, Ennis M, Hopper JL, John EM, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30(1):19\u201326.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1769_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2012.102","volume":"9","author":"SA Narod","year":"2012","unstructured":"Narod SA. Breast cancer in young women. Nat Rev Clin Oncol. 2012;9(8):460\u201370.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1769_CR31","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/bjc.2011.120","volume":"104","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe K, Gershman S, Lynch H, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384\u201392.","journal-title":"Br J Cancer"},{"key":"1769_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","volume":"124","author":"DM van der Kolk","year":"2010","unstructured":"van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124:643\u201351.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328\u201335.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T10:11:30Z","timestamp":1705918290000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01769-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Seoul National University Hospital. The need for informed consent was waived on account of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HBL and WH are co-founders and members of the DCGen Co., Ltd board of directors. HBL received research funding from Devicor Medical Product, Inc., and consulting fees from Need Inc., outside the current work. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}